Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70425 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Jessica D Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Pregnancy Complications, Pregnancy Outcome, Liver Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Inflammatory bowel disease (IBD) and chronic liver disease (CLD) are each associated with adverse pregnancy outcomes, but the impact of coexisting IBD and CLD on pregnancy remains understudied.
Aims
To assess CLD prevalence among pregnant women with and without IBD and evaluate maternal and perinatal outcomes.
Methods
We conducted a retrospective cohort study of delivery hospitalisations among women ≥ 18 years using the 2016–2022 United States National Inpatient Sample. Deliveries were categorised as IBD + CLD, IBD, CLD or neither using ICD‐10 codes. Weighted multivariable regression adjusted for demographics, comorbidities and cirrhosis.
Results
Among 21,304,600 deliveries, 178,025 had CLD, 47,555 had IBD and 680 had IBD + CLD. Chronic viral hepatitis was the most common CLD, while autoimmune liver disease accounted for half of cirrhosis in IBD + CLD. Compared to IBD or CLD, IBD + CLD had higher odds of hyperemesis gravidarum (2.64 vs. 3.68), preterm birth (2.50 vs. 1.69), hypertensive disorders of pregnancy (HDP) (1.96 vs. 1.60), caesarean delivery (1.92 vs. 1.61), perinatal mood disorder (1.75 vs. 1.45) and premature rupture of membranes (1.35 vs. 1.39). IBD + CLD had greater odds of fetal death (1.97) versus CLD and of severe maternal morbidity (1.76) and postpartum haemorrhage (1.56) versus IBD. All p ≤ 0.05.
Conclusions
Coexisting IBD and CLD confer compounded maternal and perinatal risks beyond either condition alone. Multidisciplinary care and risk‐based screening for underlying CLD in pregnant women are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Division of Liver Diseases, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, Cornell University, New York, New York, USA.
ORCID-Profile: Jessica D Lee, Konstantinos Papamichael, Adam S Cheifetz
Zitieren
APA
Lee, J. D., Papamichael, K., Grinspan, L. T., Cheifetz, A. S., Spiel, M., Kushner, T., & Rabinowitz, L. G. (2026). Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70425
Vancouver
Lee JD, Papamichael K, Grinspan LT, Cheifetz AS, Spiel M, Kushner T, et al. Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70425
BibTeX
@article{Lee2026,
author = {Lee, Jessica D and Papamichael, Konstantinos and Grinspan, Lauren T and Cheifetz, Adam S and Spiel, Melissa and Kushner, Tatyana and Rabinowitz, Loren G},
title = {Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70425}
}
EUVIMED